Loading...
Neuphoria Therapeutics Inc.
NEUP•NASDAQ
Healthcare
Medical - Pharmaceuticals
$4.23
$-0.04(-0.94%)
U.S. Market is Open • 14:22Neuphoria Therapeutics Inc. (NEUP) AI-Powered Stock Analysis
See how Neuphoria Therapeutics Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerNeuphoria Therapeutics Inc. (NEUP) Stock Overall Grade
Neuphoria Therapeutics Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Neuphoria Therapeutics Inc.'s overall stock rating.
Forecast
C+Score
57/100Financial Growth
C+Score
55/100Fundamental Growth
C+Score
54/100Key Ratios
B+Score
70/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
95/100Analyst Consensus
C+Score
50/100Neuphoria Therapeutics Inc. (NEUP) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 57/100 (C+), reflecting weak confidence in its potential. Financial Growth (55/100, C+) and Fundamental Growth (54/100, C+) highlight its stability, while Key Ratios (70/100, B+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (95/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Neuphoria Therapeutics Inc. stock grade, including financials, comparisons, and forecasts.